Lymphoma, T-Cell D016399

Description

A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.   MeSH

Subtype Terms (5)

Enteropathy-Associated T-Cell Lymphoma
23 drugs (18 approved, 5 experimental)

Lymphoma, Extranodal NK-T-Cell
53 drugs (34 approved, 19 experimental)

Lymphoma, Large-Cell, Anaplastic
145 drugs (87 approved, 58 experimental)

Lymphoma, T-Cell, Cutaneous
74 drugs (42 approved, 32 experimental)

Lymphoma, T-Cell, Peripheral
137 drugs (80 approved, 57 experimental)


Phase 2 Indicated Drugs (97)


Organization Involved with Phase 2 Indications (229)

Guangxi Medical University

GWT-TUD GmbH

Gyeongsang University

Harvard University

Hebei University

Hefei University

Hengrui Therapeutics, Inc.

Henry Ford Health System

Hospital Universitario Central de Asturias

HUYA Bioscience International

Imagine Institute

Imamura Bun-in Hospital

ImmuneOncia Therapeutics Inc.

Inje University

Innate Pharma

Innovative Therapies For Children with Cancer Consortium

Innovent Biologics (Suzhou) Co. Ltd.

International Extranodal Lymphoma Study Group

Inveresk Research

IQVIA

Isala Clinics, Zwolle, The Netherlands

James Graham Brown Cancer Center

Janssen Pharmaceutica NV

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

Jiangxi Provincial Cancer Hospital

Johannes Wesling Klinikum, Minden, Germany

Johnson and Johnson

Josep Carreras Leukaemia Research Institute

Julius-Maximilians University

Karl Landsteiner Private University of Health Sciences

Karyopharm Therapeutics Inc

Keimyung University

Klinikum Minden

Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien

Korea Cancer Center Hospital

Korea University

Kumamoto University

Kura Oncology, Inc.

Kyungpook University

Louisiana State University

Mahidol University

Mayo Clinic

McGill University

McMaster University

Medical College of Wisconsin

Medical University of Vienna

Memorial Sloan-Kettering Cancer Center

Merck

Merck KGaA

Millennix

miRagen Therapeutics, Inc.

Monash University

Morristown Memorial Hospital

Nanjing Medical University

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Nanjing Sanhome Pharmaceutical, Co., Ltd.

National Cancer Center, Korea

National Heart, Lung, and Blood Institute (NHLBI)

National Institutes of Health (NIH)

Neumedicines Inc.

New York University

Northwestern University

Norwegian University of Science and Technology

Ohio State University

Okayama University

Onxeo

Ortho Biotech, Inc.

Osaka University

Ospedale Maggiore Azienda Sanitaria Universitaria Trieste Ematologia

Otsuka

Pennsylvania State University

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Peter MacCallum Cancer Centre

Pfizer

PharmaMar

Philipps University of Marburg

Pretoria Academic Hospital

Pusan National University

Rhizen Pharmaceuticals SA

Rigel Pharmaceuticals

Roche

Rochester Skin Lymphoma Medical Group, PLLC

Royal Marsden Hospital NHS Trust

Rutgers University

RWTH Aachen University

Scott and White Healthcare

Shandong New Time Pharmaceutical Co., LTD

Shandong Tumor Hospital

Shandong University

Shantou University

Shijiazhuang Pharma Group (CSPC)

Sichuan University

Simcere Pharmaceutical Co., Ltd

Singapore General Hospital

Siriraj Hospital

Solasia Pharma K.K.

Sorrento Therapeutics, Inc.

Southwest Oncology Group

Stanford University

State University of New York, Buffalo

State University of New York, Syracuse

Stellenbosch University

Sungkyunkwan University

Takeda

Temple University

TetraLogic Pharmaceuticals

The Christie NHS Foundation Trust

The First People's Hospital of Lianyungang

The Lymphoma Study Association

The National Cancer Center

The Thai Lymphoma Study Group

The University of Texas, Dallas

Thomas Jefferson University

Tibotec

Tsinghua University

Universidad Autonoma de Barcelona

Organization Involved with Other Experimental Indications (4)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.